Public Event Detail
The top 10 pharma M&A deals of 2022
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Event summary
In 2022, despite recession fears and inflation, the pharmaceutical and life sciences sector saw significant M&A activity, with Amgen and Pfizer leading the way with multi-billion dollar acquisitions. This article details the top 10 pharma M&A deals of the year, each worth at least $1 billion, highlighting major transactions involving companies like Horizon Therapeutics, Biohaven Pharmaceuticals, and Global Blood Therapeutics. These deals aimed to expand pipelines in areas like rare diseases, oncology, and neurological disorders, demonstrating continued strategic investments within the industry.